Abstract 3876: Prognostic and predictive value of the Clearseq1-4 tumor microenvironment classification in localized and metastatic clear-cell renal cell carcinoma.

Abstract PURPOSE: The ccrcc1-4 transcriptomic subtypes were previously identified on fresh frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value post-nephrectomy/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). We aimed to extend and validate the ccrcc1-4 classifier on formalin-fixed paraffin-embedded (FFPE) tissues and to validate its prognostic and predictive value across the RCC treatment landscape. EXPERIMENTAL DESIGN: RNA sequencing of tumoral FFPE tissue was performed. A classifier called Clearseq was designed to determine ccrcc1-4 subtypes. Subtypes were correlated with outcome after surgical and systemic therapies. External validation was pursued as well as characterization at single-cell transcriptomic level. RESULTS: A total of 668 tumoral samples (337 primary tumors and 331 metastases) from 364 patients were assigned into ccrcc1, ccrcc2, ccrcc3 and ccrcc4-tumors. The angiogenic ccrcc2-subtype had a favorable prognosis after nephrectomy in localized setting, after cytoreductive nephrectomy and upon metastasectomy with curative intent and was correlated with improved outcome on first-line VEGFR-TKIs. Ccrcc4-tumors were enriched for sarcomatoid features and had the largest treatment benefit on immune checkpoint blockade (ICB) treatment in any line, resulting in overall survival outcomes comparable to those of less aggressive subtypes. These findings were corroborated in a post-nephrectomy cohort, and external cohorts of metastatic patients treated with ICB and/or angiogenesis inhibitors. CONCLUSIONS: We validated the Clearseq classifier to predict ccrcc1-4 molecular subtype on FFPE tissues and confirmed its performance with respect to previous biomarker findings for both surgical and systemic treatment approaches. Citation Format: Benoit Beuselinck, Lisa Kinget, Edward Mctaggart, Octavie Demeulenaere, Edouard Roussel, Bram Boeckx, Jessica Zucman-Rossi, Gabrielle Couchy, Henri Vandermeulen, Liesbeth De Wever, Marcella Baldewijns, Agnieszka Wozniak, Diether Lambrechts, Stefan Naulaerts, Abhishek D. Garg, Annelies Verbiest, Maarten Albersen. Prognostic and predictive value of the Clearseq1-4 tumor microenvironment classification in localized and metastatic clear-cell renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3876.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-3876
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3876: Prognostic and predictive value of the Clearseq1-4 tumor microenvironment classification in localized and metastatic clear-cell renal cell carcinoma.

Liesbeth De Wever, Henri Vandermeulen, Benoit Beuselinck, Stefan Naulaerts et al.
Cancer Research
Renal cell carcinoma treatment
article

Abstract 3876: Prognostic and predictive value of the Clearseq1-4 tumor microenvironment classification in localized and metastatic clear-cell renal cell carcinoma.

Liesbeth De Wever, Henri Vandermeulen, Benoit Beuselinck, Stefan Naulaerts, Gabrielle Couchy, Annelies Verbiest, Agnieszka Woźniak, Marcella Baldewijns, Abhishek D. Garg, Bram Boeckx, Lisa Kinget, Octavie Demeulenaere, Jessica Zucman-Rossi, Edward Scott McTaggart, E. Roussel, Maarten Albersen, Diether Lambrechts
article en

Abstract

Abstract PURPOSE: The ccrcc1-4 transcriptomic subtypes were previously identified on fresh frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value post-nephrectomy/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). We aimed to extend and validate the ccrcc1-4 classifier on formalin-fixed paraffin-embedded (FFPE) tissues and to validate its prognostic and predictive value across the RCC treatment landscape. EXPERIMENTAL DESIGN: RNA sequencing of tumoral FFPE tissue was performed. A classifier called Clearseq was designed to determine ccrcc1-4 subtypes. Subtypes were correlated with outcome after surgical and systemic therapies. External validation was pursued as well as characterization at single-cell transcriptomic level. RESULTS: A total of 668 tumoral samples (337 primary tumors and 331 metastases) from 364 patients were assigned into ccrcc1, ccrcc2, ccrcc3 and ccrcc4-tumors. The angiogenic ccrcc2-subtype had a favorable prognosis after nephrectomy in localized setting, after cytoreductive nephrectomy and upon metastasectomy with curative intent and was correlated with improved outcome on first-line VEGFR-TKIs. Ccrcc4-tumors were enriched for sarcomatoid features and had the largest treatment benefit on immune checkpoint blockade (ICB) treatment in any line, resulting in overall survival outcomes comparable to those of less aggressive subtypes. These findings were corroborated in a post-nephrectomy cohort, and external cohorts of metastatic patients treated with ICB and/or angiogenesis inhibitors. CONCLUSIONS: We validated the Clearseq classifier to predict ccrcc1-4 molecular subtype on FFPE tissues and confirmed its performance with respect to previous biomarker findings for both surgical and systemic treatment approaches. Citation Format: Benoit Beuselinck, Lisa Kinget, Edward Mctaggart, Octavie Demeulenaere, Edouard Roussel, Bram Boeckx, Jessica Zucman-Rossi, Gabrielle Couchy, Henri Vandermeulen, Liesbeth De Wever, Marcella Baldewijns, Agnieszka Wozniak, Diether Lambrechts, Stefan Naulaerts, Abhishek D. Garg, Annelies Verbiest, Maarten Albersen. Prognostic and predictive value of the Clearseq1-4 tumor microenvironment classification in localized and metastatic clear-cell renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3876.

Cancer ResearchVol. 86(7_Supplement)
Inserm (FR), Province of Antwerp (BE), Catholic University of America (US), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 31%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.